BACKGROUND: Several studies revealed that MSC from human bone marrow can downregulate graft-versus-host disease (GVHD) after allogeneic HSCT. METHODS: Herein we present 50 patients with acute GVHD who got 74 (1-4) MSC infusions for 54 separate episodes of aGVHD. RESULTS: aGVHD was defined as steroid resistant grade IV aGVHD in 42 cases. The major presentation was gastrointestinal GVHD; two (n=18) or more (n=21) systems were involved in the majority of cases. The 1(st) infusion with MSC was given on day +27 (range, 1 to 136); d+45 (range, +11 to +150) post diagnosis of aGVHD and HSCT, respectively. In 2/3 of the cases treatment was performed with frozen stocked MSCs; in 62 cases early passages (1-3) were used. The median number of infused cells was 1.14±0.47 million per kg in the first injection and up to 4.27 (1.70±1.10) millions in total. The two patients with aggressive liver GVHD received MSCs injections intra hepatic arteries without changes of blood flow or evidence cytolysis, but also without a visible effect. Disease free survival at 3.6 years was 56%. We observed better overall survival in patients with GVHD grade < 4, in responders to the 1(st) treatment with MSC, and in pediatric group. The multivariate analysis demonstrated independent influence on survival of initial response and younger age. There were no immediate or late toxicity or side effects. CONCLUSION: Injection of MSCs seems to be a promising and safe treatment of GVHD. The encouraging results obviously should be confirmed in a randomized prospective study.
BACKGROUND: Several studies revealed that MSC from human bone marrow can downregulate graft-versus-host disease (GVHD) after allogeneic HSCT. METHODS: Herein we present 50 patients with acute GVHD who got 74 (1-4) MSC infusions for 54 separate episodes of aGVHD. RESULTS: aGVHD was defined as steroid resistant grade IV aGVHD in 42 cases. The major presentation was gastrointestinal GVHD; two (n=18) or more (n=21) systems were involved in the majority of cases. The 1(st) infusion with MSC was given on day +27 (range, 1 to 136); d+45 (range, +11 to +150) post diagnosis of aGVHD and HSCT, respectively. In 2/3 of the cases treatment was performed with frozen stocked MSCs; in 62 cases early passages (1-3) were used. The median number of infused cells was 1.14±0.47 million per kg in the first injection and up to 4.27 (1.70±1.10) millions in total. The two patients with aggressive liver GVHD received MSCs injections intra hepatic arteries without changes of blood flow or evidence cytolysis, but also without a visible effect. Disease free survival at 3.6 years was 56%. We observed better overall survival in patients with GVHD grade < 4, in responders to the 1(st) treatment with MSC, and in pediatric group. The multivariate analysis demonstrated independent influence on survival of initial response and younger age. There were no immediate or late toxicity or side effects. CONCLUSION: Injection of MSCs seems to be a promising and safe treatment of GVHD. The encouraging results obviously should be confirmed in a randomized prospective study.
Authors: Lindolfo da Silva Meirelles; Theodore T Sand; Robert J Harman; Donald P Lennon; Arnold I Caplan Journal: Tissue Eng Part A Date: 2009-02 Impact factor: 3.845
Authors: Reza Izadpanah; Deepak Kaushal; Christopher Kriedt; Fern Tsien; Bindiya Patel; Jason Dufour; Bruce A Bunnell Journal: Cancer Res Date: 2008-06-01 Impact factor: 12.701
Authors: L C J Te Boome; C Mansilla; L E van der Wagen; C A Lindemans; E J Petersen; E Spierings; K A Thus; K Westinga; M Plantinga; M Bierings; A E C Broers; M L H Cuijpers; G W van Imhoff; J J Janssen; C Huisman; S Zeerleder; G Huls; J J Boelens; N M Wulffraat; I C M Slaper-Cortenbach; J Kuball Journal: Leukemia Date: 2015-04-03 Impact factor: 11.528
Authors: José R García; Miguel Quirós; Woojin M Han; Monique N O'Leary; George N Cox; Asma Nusrat; Andrés J García Journal: Biomaterials Date: 2019-08-02 Impact factor: 12.479
Authors: C Fernández-Maqueda; R Gonzalo-Daganzo; C Regidor; T Martín-Donaire; R Sánchez; J L Bueno; G Bautista; A De Liglesia; Y Gutiérrez; M García-Berciano; R Forés; A Royuela; M N Fernández; R F Duarte; J R Cabrera-Marín Journal: Bone Marrow Transplant Date: 2017-08-07 Impact factor: 5.483